News & Updates
Filter by Specialty:
Adjuvant atezolizumab improves DFS in early-stage NSCLC
In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.
Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021
Chronic constipation not a risk factor for later colorectal cancer
Individuals with chronic constipation do not seem to be at increased risk of developing subsequent colorectal cancer as compared with their peers who do not have the gastrointestinal condition, as reported in a study.
Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
26 Oct 2021
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
26 Oct 2021
Minimally invasive surgery feasible for nonendometroid endometrial cancers
Minimally invasive surgery for nonendometrioid endometrial cancer performs comparably as open surgery, yielding similar survival outcomes, a recent study has found.
